市場調査レポート
商品コード
1226534
トクチノ新薬の考察と市場予測(2032年)TOCTINO Drug Insight and Market Forecast - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
トクチノ新薬の考察と市場予測(2032年) |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
当レポートでは、トクチノ新薬の主要7市場(米国・ドイツ・フランス・イタリア・スペイン・英国・日本)について調査分析し、作用機序、用法と用量、研究開発活動についての考察、市場予測などを提供しています。
"TOCTINO Drug Insight and Market Forecast - 2032" report provides comprehensive insights about TOCTINO for Hand Eczema (HE) in EU4 and the UK. A detailed picture of the TOCTINO for Hand Eczema in EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019-2032 is provided in this report along with a detailed description of the TOCTINO for Hand Eczema. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the TOCTINO market forecast, analysis for Hand Eczema inEU4 and the UK, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Hand Eczema.
TOCTINO (alitretinoin) is an endogenous metabolite of vitamin A and belongs to the retinoid, a class of drugs that have been used to treat many skin disorders, including acne vulgaris, psoriasis, etc., for around two decades.
Alitretinoin is an approved and marketed product in multiple European countries and is indicated for use in adults with severe chronic HE that is unresponsive to treatment with potent topical corticosteroids. Patients in whom eczema has hyperkeratotic features predominantly are more likely to respond to treatment than those in whom eczema predominantly presents as pompholyx. However, it is not approved in the US and Japan.
Dosage and administration
TOCTINO is available as red-brown soft gelatin capsules containing 10 or 30 mg of alitretinoin. TOCTINO (alitretinoin) is a convenient once-daily capsule to be taken with food. The recommended dose for TOCTINO is 10 mg or 30 mg once daily. The recommended starting dose is 30 mg in most patients, and a treatment course lasts up to 12-24 weeks, depending on response. A dose reduction to 10 mg once daily may be considered in patients with unacceptable adverse reactions to the 30 mg dose.
Mechanism of action
Alitretinoin has a distinct uniqueness among all retinoids in that it has the ability to bind to all subclasses of retinoic acid receptors (RARs) and retinoid X receptors (RXRs). The pharmacological action of retinoids may be explained by their effects on cell proliferation, cell differentiation, apoptosis, angiogenesis, keratinization, sebum secretion, and immunomodulation. The mechanism by which alitretinoin alleviates the signs and symptoms of CHE is unclear. It has, however, been suggested that by activating RXRs, alitretinoin may stimulate TH2 immune functions, thus ameliorating the pathology encountered in CHE. Alitretinoin has demonstrated immunomodulatory and anti-inflammatory effects that are relevant to skin inflammation. It suppresses the production of chemokines that are involved in the recruitment of leukocytes to sites of skin inflammation, reduces the expansion of T lymphocytes and antigen-presenting cells, and inhibits the effect on cell differentiation. CXCR3 ligands and CCL20 chemokines, expressed in eczematous skin lesions, are downregulated by alitretinoin in cytokine-stimulated keratinocytes and dermal endothelial cells. In addition, alitretinoin suppresses the expansion of cytokine-activated leucocyte subsets and antigen-presenting cells. It has been observed that in humans, alitretinoin only minimally affects sebum secretion.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
TOCTINO Analytical Perspective by DelveInsight
This report provides a detailed market assessment of TOCTINO in Hand Eczema (HE) in EU4 (Germany, France, Italy, and Spain) and the United Kingdom. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of TOCTINO in Hand Eczema (HE) covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions